 Mr. Musil brings a deep understanding of capital markets, financial strategy and MA; experience to the Company and we are delighted to have him join Catalysts executive leadership team, said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. His business and financial expertise will be instrumental in building our pipeline in rare hematologic and complement-mediated disorders. 